EHA 2025

Nico Gagelmann: Lower chronic graft-versus-host disease with ruxolitinib plus photopheresis post-transplant

Nico Gagelmann, Young National Society Ambassador at European Hematology Association (EHA), shared on LinkedIn about a recent paper by Iryna Lastovytska et al. published in Haematologica:

“Finally out: Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem-cell transplantation”

Authors: Iryna Lastovytska et al.

Nico Gagelmann

cancer Iryna Lastovytska Nico Gagelmann OncoDaily Oncology ruxolitinib